For brokers, referrers and the partnership teams at data companies. A list of biotech companies gives you names. To introduce one to an AI data buyer you also need to know which segment it is in, which records it likely holds, whether it is still operating, and what its IP and regulatory position allows. This page covers all four, with a preview drawn from our scored segment of US labs, CROs and life-science companies.
Or keep the full list always current with Pro at $299 a month, through the API. Compare plans.
Searches for a list of biotech companies, or a list of biotech companies in the USA, come from investors, job seekers, suppliers and students, and the lists that answer them are built for those readers: names, funding stages, headquarters, perhaps a pipeline chart. City versions are common too, for well-known clusters such as Boston and San Diego. This page does not split companies by city, and it does not try to count biotech companies anywhere.
A broker, or a sourcing team at a data company, needs different columns. Is the company still operating? Has it existed long enough to hold several years of records? Which of its records are its own, and which belong to partners, licensors or patients? Does it meet the size and location rules that buyer programs publish? Without those columns, every name on a list is a guess, and every introduction costs you credibility with the buyer when it fails review.
Our list answers the first set of questions at company level. It is one of our 20 US sector lists and covers US labs, CROs and life-science companies. Every company on it is verified active: the domain resolves, is not expired, is not parked and shows no error or placeholder page. Companies from all four biotech segments below appear in it, next to testing labs and contract research organizations. Each company carries a Data Asset Score, a grade, the data it likely holds, its history and an activity status. Everything after that is judgment, and most of this page is about that judgment.
Biotech is not one kind of company. The segment predicts what the company writes down, who else has rights in it, and how close its records sit to its main asset.
Companies developing medicines: small molecules, antibodies and other biologics, cell and gene therapies, vaccines.
Discovery and assay data, notebook entries, preclinical study files, process development and manufacturing records, regulatory correspondence, clinical operations often run through CROs.
The R&D record sits next to the pipeline, the company's main asset. Look first at quality, operations and documentation.
Companies that sell to other scientists: reagents and kits, instruments and lab equipment, research software and computational platforms.
Technical support tickets, application notes and protocols, knowledge bases, customer portals and orders, product test records, software code and issue histories.
Often the most practical segment: much of the record is about how customers use products, not about a private pipeline.
Companies that develop and run tests: lab-developed tests, test kits, genomic and molecular testing services.
Assay development and validation, quality system records, design files for kits, lab operations and scheduling, support for ordering clinics and labs.
Any lab reporting results on patients holds patient data. The non-patient record, validation and quality, is the possible scope.
Companies that engineer organisms and DNA: strain and enzyme engineering, DNA design and synthesis, biomanufacturing.
Design, build and test cycles, strain and construct records, fermentation and scale-up notes, automation logs, design software and scripts.
Highly structured and experimental, and close to trade secrets. Some technology may also raise export control questions.
Read across a row to see how the same kind of record changes from segment to segment. The row labels match the likely data assets a Data Asset Score can show, so you can line up a scored company against this table quickly.
| Record type | Therapeutics | Tools and platforms | Diagnostics | Synthetic biology |
|---|---|---|---|---|
| Lab, study and R&D records | Discovery, assay and preclinical work, close to the pipeline | Application development, product testing, method notes | Assay development and validation | Design, build and test cycles, strain records |
| Knowledge base, SOPs and documentation | GLP and GMP procedures, process documentation | Product manuals, protocols, application notes, internal QC procedures | Quality system, lab procedures, kit instructions | Biomanufacturing and lab automation procedures |
| Support tickets and chat transcripts | Few, mostly with partners and vendors | Often large: technical questions from scientists using products | Questions from ordering clinics and labs, often with patient details | Customer projects at platform companies |
| Project histories and case files | Program management, partner governance | Product development and release histories | Test launch and validation projects | Customer and partner programs |
| Code with commit and issue history | Analysis and bioinformatics pipelines | Instrument software, analysis tools, platform code | Bioinformatics pipelines, lab software | Design software, automation scripts |
Biotech is built on expert judgment that rarely reaches the public record. That is what makes some of its operating records interesting, and why the qualification work on this page matters.
Published papers report what worked. Internal records show what was tried and dropped, and why. Negative results almost never get published, so that part of the record is rare.
Validation reports, deviation records and support tickets follow templates, so the same kind of expert decision appears many times, made by different people.
Practitioners say evaluations are worth about 10x raw data, and full environments reach 6 to 8 figures. Both need scientists who know the work, which biotechs employ.
Tools companies deserve a special mention. A reagent or instrument maker answers technical questions from scientists every day: why an assay failed, how to adapt a protocol, what a strange reading means. Those answers, written by application scientists over many years, are a record of expert troubleshooting that is mostly about the customer's problem rather than the company's secrets. That does not make them free to license. Customer names, customer data and anything covered by customer contracts still need to come out, and the company decides whether it wants to do this at all. But it explains why tools companies often look strong on paper.
Therapeutics developers are the opposite case. Their R&D record may be the most valuable thing they own, and it is tied to patents, partners and, later, to patients. A broker who leads with that record will rarely get past the first call. A broker who asks about quality systems, training, project management and internal documentation, the things every developer builds and few treat as secret, has a more realistic opening. For more on how buyers weigh raw records against evaluations, read raw data vs evaluations vs environments.
General information, not legal advice. Each card ends with the question to put to the company's counsel. You do not need the answers to introduce a company, but you do need to know the questions exist, so you never pitch what cannot be sold.
Disclosing unpublished results or methods may affect patent positions, including inventions not yet filed.
Ask IP counselCould anything in scope reveal an unfiled invention, a target or a compound?
Processes, strains, cell lines and formulations are often protected as secrets, which only works while they stay secret.
Ask IP counselWhich records describe processes the company protects as trade secrets?
Collaborations, licensed-in technology and co-development deals usually define who owns data and results.
Ask counselWhich agreements give a partner or licensor rights over data the company holds?
Government grants and university agreements can set terms on data, results and how they are shared.
Ask counselDo any grant or sponsored research terms restrict use or licensing?
Diagnostics labs and clinical work involve patient data. HIPAA's de-identification standard names Safe Harbor and Expert Determination.
Ask counselDo any systems hold patient data, and can they be fully excluded?
Some states have laws that deal specifically with genetic information, on top of general health privacy rules.
Ask counselDoes the company hold genetic data about people, and which state laws apply?
GLP, GMP and GCP rules, and 21 CFR Part 11 for electronic records, govern how regulated records are kept and changed.
Ask counsel and QADoes copying regulated records affect retention, audit trails or validated systems?
Some biological materials, equipment and technical data fall under export control rules, which can reach data shared abroad.
Ask counselDoes any record contain controlled technical data, and where would the buyer process it?
As published, checked 7 October 2026. Company ranges are what each program states, not offers. Referral amounts are paid only under each program's own terms.
To see which published rules a specific company meets, use the check against buyer rules: it reads the company's public pages and compares team size, location, history and systems with the published rules of micro1, Mode and Grepped, with quotes.
Six steps, cheapest first. None of them involves seeing a record, and the first four take minutes per company.
The score is a triage tool. It ranks companies from 0 to 100 for the data AI buyers want, gives a grade, lists the data the company likely holds and shows its history and activity status. It covers nine factor groups: history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status. It is built on our index of 102 million domains, 99.99% of the active internet, with domain history.
In the example, a broker sees a long history, strong documentation and customer systems, and support tickets as a likely asset. That pattern fits a tools company. The next steps are human ones: confirm the segment on the company's site, run the check against buyer rules, and think about which of those support records involve customer data.
What the score does not do matters as much. It is an estimate from public signals, not a valuation, not an offer and not proof that the company wants to sell anything. It cannot see inside a company's systems or contracts. Use it to decide which companies to look at first, then do the qualification work. You can try it on any company in the free demo, which is limited per day.
Every Data Asset Score shows one of four statuses. In biotech, where companies are acquired, merged and wound down often, it is the field to read before any other.
| Status | What it tells you | What to do next |
|---|---|---|
| Active | The company appears to be operating under its own name. | The normal path: segment, likely data assets, buyer rules, then an introduction through the program. |
| Winding down or acquired | The people who could sign may have changed. The records may now sit with an acquirer, a parent company or whoever handles the wind-down. | Find out who controls the records before anything else. Buyers have bid for archive data in this situation; see the Spirit Airlines case below. |
| Parked | The domain is parked rather than running a company website. | Not a partner as it stands. Check whether the business moved to another name or domain. |
| Unreachable | The company's website was not reachable when it was last scored. | Check again later before you draw a conclusion either way. |
These companies appear in the visible top 5 of the free public preview, as shown on 8 October 2026, and are plainly biotech or life-science tools companies. We list only those, with the fields the preview shows, plus our own segment label. The one top-5 company that is not plainly biotech or tools is left out here rather than labeled, and the rows below the top 5 stay masked on the preview.
| Preview rank | Company website | Biotech segment (our label) | Score | Status | Online since | Likely data assets |
|---|---|---|---|---|---|---|
| 1 | promega.com | Tools: reagents, media and kits | 78B | Active | 1993 | Support tickets and chat transcriptsKnowledge base, SOPs and documentationCustomer accounts and portal activityOrder and transaction records |
| 3 | schrodinger.com | Tools: research software and computing | 73B | Active | 1996 | Support tickets and chat transcriptsKnowledge base, SOPs and documentationCustomer accounts and portal activityOrder and transaction records |
| 4 | quidel.com | Diagnostics | 67B | Active | 1994 | Support tickets and chat transcriptsKnowledge base, SOPs and documentationCustomer accounts and portal activityRecruiting and hiring records |
| 5 | gene.com | Therapeutics | 65B | Active | 1987 | Support tickets and chat transcriptsKnowledge base, SOPs and documentationCustomer accounts and portal activityRecruiting and hiring records |
Three of the four biotech segments already show in the visible top 5: tools and platforms, diagnostics and therapeutics. Synthetic biology companies are in the full list as well. To reach them, work through the full list, either as the one-time download or through the API, filter by score, and place each company in a segment yourself using the tiles above. For contract research organizations in the same segment, see the list of contract research organizations.
No single signal decides anything. Taken together, they tell you whether a company is worth a buyer's review time, and yours.
Last checked: 8 October 2026. A free preview is public, with the top 5 visible. The full list of US labs, CROs and life-science companies can be bought once for $249, or kept always current through the API on Pro and Scale.
US labs, CROs and life-sciences list: $249 one-time, on sale from 1,000 verified companies
No. We do not publish a count of biotech companies in the USA or in any city. Biotech companies sit in our US labs, CROs and life-science companies list, one of 20 US sector lists, where every company is verified active and scored. Therapeutics, tools, diagnostics and synthetic biology companies all appear in it, next to testing labs and contract research organizations.
No. We do not build city lists. The segment covers US companies, and each company carries the same fields wherever it is based: Data Asset Score, grade, likely data assets, history and activity status.
There is no single answer, and no buyer publishes one. Tools and platform companies often hold large customer-facing records such as support tickets and documentation, which sit further from a proprietary pipeline. Therapeutics developers hold rich R&D records, but those sit closest to patents and partner rights. Qualify each company on its own records, size and status.
That is a question for the company’s IP counsel, not for a broker. Disclosing unpublished results or methods may affect patent positions and trade secrets, and collaboration or grant terms may give others rights in the data. General information, not legal advice.
A score from 0 to 100 for the data AI buyers want, with a grade, the data the company likely holds, its history and an activity status: active, winding down or acquired, parked, or unreachable. It covers nine factor groups: history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status. It is an estimate from public signals, not a valuation or an offer.
Treat it as a different track. The people who could sign may have changed, and the records may now belong to an acquirer, a parent company or whoever is handling the wind-down. Find out who controls the records before you introduce anyone. We do not sell a wind-down list; the status appears on every score.
Two ways. Buy the US labs, CROs and life-science companies list once for $249: a CSV snapshot with no updates, with download links right after payment that are also emailed, valid 30 days with 5 downloads per file. Or keep it always current through the API: the Pro plan, $299 a month, returns it as JSON, up to 100 companies per call, with paging, and the Scale plan, $799 a month, adds the one-file bulk CSV export. Payment is by PayPal or card; on a plan, the key appears in your dashboard after payment.
No. Everything is company level only. We do not publish or sell names, emails or phone numbers of people.
Start with the free preview, score any company in the demo, and check a target against published buyer rules in about 20 seconds. When you need the whole list, buy it once for $249, or get it always current on Pro through the API.